Neuronetics Inc
STIM4.670USD
+0.250+5.66%
Market hours （ET）Quotes delayed by 15 min
307.38MMarket Cap
LossP/E TTM
More Details of Neuronetics Inc Company
Neuronetics, Inc. is a medical technology company focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its NeuroStar Advanced Therapy for Mental Health is a non-drug, noninvasive treatment for people suffering from neurohealth conditions. In addition to selling the NeuroStar system and associated treatment sessions to customers, it operates treatment centers across the United States, offering both NeuroStar Advanced Therapy (transcranial magnetic stimulation or TMS) and Spravato (esketamine nasal spray) for the treatment of major depressive disorder (MDD) and other mental health disorders. NeuroStar Advanced Therapy is the TMS treatment for MDD in adults. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. It provides more than 1.68 million treatments to over 51,000 patients struggling with depression.
Company Info
Ticker SymbolSTIM
Company nameNeuronetics Inc
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Number of employees716
Security typeOrdinary Share
Fiscal year-endJun 28
Address3222 Phoenixville Pike
CityMALVERN
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code19355
Phone18776007555
Websitehttps://neurostar.com/neuronetics/
Ticker SymbolSTIM
IPO dateJun 28, 2018
CEOMr. Keith J. Sullivan
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.02M
+1.50%
Mr. Keith J. Sullivan
Mr. Keith J. Sullivan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.61M
--
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
578.24K
+6.69%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
327.90K
+10.07%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
178.03K
+20.27%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.02M
+1.50%
Mr. Keith J. Sullivan
Mr. Keith J. Sullivan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.61M
--
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
578.24K
+6.69%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
327.90K
+10.07%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
178.03K
+20.27%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
18.66M
58.35%
Treatment sessions
9.76M
30.53%
NeuroStar Advanced Therapy System
3.01M
9.41%
Other
544.00K
1.70%
By RegionUSD
Name
Revenue
Proportion
United States
31.48M
98.46%
International
492.00K
1.54%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Clinic revenue
18.66M
58.35%
Treatment sessions
9.76M
30.53%
NeuroStar Advanced Therapy System
3.01M
9.41%
Other
544.00K
1.70%
Shareholding Stats
Updated: Thu, Jul 17
Updated: Thu, Jul 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
36.82%
The Vanguard Group, Inc.
3.50%
Cucuz (Sasha)
3.08%
Sullivan (Keith J)
2.44%
Balyasny Asset Management LP
2.15%
Other
52.00%
Shareholders
Shareholders
Proportion
Madryn Asset Management, LP
36.82%
The Vanguard Group, Inc.
3.50%
Cucuz (Sasha)
3.08%
Sullivan (Keith J)
2.44%
Balyasny Asset Management LP
2.15%
Other
52.00%
Shareholder Types
Shareholders
Proportion
Private Equity
36.82%
Hedge Fund
12.75%
Individual Investor
9.48%
Investment Advisor
7.53%
Investment Advisor/Hedge Fund
3.50%
Research Firm
1.84%
Pension Fund
0.09%
Bank and Trust
0.03%
Other
27.96%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
183
47.01M
71.42%
-4.23M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
2023Q2
222
21.10M
73.37%
-11.20M
2023Q1
226
22.33M
78.62%
-9.89M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Madryn Asset Management, LP
24.24M
36.82%
--
--
Mar 24, 2025
The Vanguard Group, Inc.
2.31M
3.5%
+1.02M
+79.97%
Mar 31, 2025
Cucuz (Sasha)
2.02M
3.08%
+30.00K
+1.50%
May 22, 2025
Sullivan (Keith J)
1.61M
2.44%
--
--
Mar 24, 2025
Balyasny Asset Management LP
1.42M
2.15%
-64.72K
-4.37%
Mar 31, 2025
Ikarian Capital LLC
1.10M
1.67%
+1.10M
--
Mar 31, 2025
Masters Capital Management, L.L.C.
1.00M
1.52%
-500.00K
-33.33%
Mar 31, 2025
Manatuck Hill Partners, LLC
920.00K
1.4%
+920.00K
--
Mar 31, 2025
Susquehanna International Group, LLP
761.91K
1.16%
+761.91K
--
Mar 31, 2025
Two Sigma Investments, LP
703.67K
1.07%
+703.67K
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
AdvisorShares Psychedelics ETF
6.11%
Invesco NASDAQ Future Gen 200 ETF
0.4%
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
View more
AdvisorShares Psychedelics ETF
Proportion6.11%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.4%
iShares Micro-Cap ETF
Proportion0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.02%
iShares Russell 2000 Growth ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
